Quantcast

Birkmayer NADH Assists Those Lacking Energy with Natural Energy Production

November 21, 2013

Co-E1 NADH helps chronic fatigue sufferers with more energy.

(PRWEB) November 21, 2013

Chronic fatigue is one of the USA's most debilitating epidemics. Until now, there has been little in the way of a quick fix. Yet, if the hype is to be believed, a new tablet known as Co-E1 NADH could be the cure thousands have been hoping for.

Described as 'human rocket fuel', it's an over-the- counter treatment for sufferers of fatigue that, claim the makers, restores energy and vitality quickly. The one-tablet-a-day supplement, taken at breakfast time, is also claimed to be a successful treatment for chronic fatigue syndrome, with one in three sufferers reporting improvements in their symptoms after 12 weeks.

Known as the power-pill, Co-E1 NADH 20mg is also being used by Olympic athletes to boost energy levels, and by highflier executives to overcome stress and exhaustion. Students are also taking the Co-E1 NADH 10mg pills, which retail for about $24.00 for 30, as a pre-exam energy-booster.

Sales of NADH are at record levels in America and are increasing in Britain, Europe and Asia too, either through the internet or in health-food shops. Birkmayer NADH is the manufacturer of the original Dr Birkmayer ENADA NADH brand and is the main internet supplier, lists a catalogue of beneficial affects: 'NADH energises the body and the brain, giving increased energy and mental activity,' would-be buyers are told.

The theory behind NADH – or nicotinamide adrenine dinucleotide hydride, whose active form is marketed as ENADA Co-E1 – is that it is a coenzyme found naturally in cells and plays a key role in energy production in those cells. It's also said to be a powerful antioxidant which protects the body from damage-causing free radicals involved in more than 80 degenerative disorders, including arthritis and heart disease. Much of the research centres on its use in treating patients with chronic fatigue syndrome.

Research carried out by immunologist Dr Joseph Bellanti found that eight out of 26 chronic fatigue syndrome sufferers achieved a 10% improvement in their symptoms. It is being suggested, too, that the supplement may be useful in treating other degenerative conditions, including Parkinson's disease.

Read More at the Birkmayer NADH websites http://www.enadh.com and http://www.co-e1.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/11/prweb11351429.htm


Source: prweb



comments powered by Disqus